Metropolitan Life Insurance Co. NY increased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 5.9% during the first quarter, Holdings Channel reports. The institutional investor owned 60,126 shares of the biotechnology company’s stock after buying an additional 3,339 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in BioCryst Pharmaceuticals were worth $505,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in BioCryst Pharmaceuticals by 49.1% in the first quarter. Vanguard Group Inc. now owns 5,011,763 shares of the biotechnology company’s stock valued at $42,098,000 after buying an additional 1,651,292 shares in the last quarter. RA Capital Management LLC boosted its position in BioCryst Pharmaceuticals by 16.7% in the first quarter. RA Capital Management LLC now owns 3,489,795 shares of the biotechnology company’s stock valued at $29,314,000 after buying an additional 500,000 shares in the last quarter. State Street Corp boosted its position in BioCryst Pharmaceuticals by 8.6% in the first quarter. State Street Corp now owns 2,272,104 shares of the biotechnology company’s stock valued at $19,083,000 after buying an additional 179,216 shares in the last quarter. Jennison Associates LLC boosted its position in BioCryst Pharmaceuticals by 36.1% in the first quarter. Jennison Associates LLC now owns 1,844,636 shares of the biotechnology company’s stock valued at $15,495,000 after buying an additional 489,536 shares in the last quarter. Finally, FMR LLC boosted its position in BioCryst Pharmaceuticals by 97.5% in the first quarter. FMR LLC now owns 1,456,885 shares of the biotechnology company’s stock valued at $12,238,000 after buying an additional 719,162 shares in the last quarter. 84.49% of the stock is currently owned by hedge funds and other institutional investors.

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) traded up 5.10% on Friday, hitting $4.53. 824,839 shares of the company’s stock were exchanged. The firm’s market cap is $364.34 million. The stock’s 50 day moving average is $5.36 and its 200 day moving average is $6.28. BioCryst Pharmaceuticals, Inc. has a 12 month low of $3.75 and a 12 month high of $9.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.02. The firm had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $5.79 million. BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. BioCryst Pharmaceuticals’s revenue was down 35.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.22) EPS. On average, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post ($0.72) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “BioCryst Pharmaceuticals, Inc. (BCRX) Shares Bought by Metropolitan Life Insurance Co. NY” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.watchlistnews.com/biocryst-pharmaceuticals-inc-bcrx-shares-bought-by-metropolitan-life-insurance-co-ny/1479334.html.

BCRX has been the topic of several research analyst reports. Noble Financial reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a report on Saturday, May 6th. Zacks Investment Research raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Monday, May 1st. ValuEngine cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. Needham & Company LLC reissued a “hold” rating on shares of BioCryst Pharmaceuticals in a report on Friday, May 19th. Finally, BidaskClub raised shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. BioCryst Pharmaceuticals has a consensus rating of “Hold” and an average target price of $8.00.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX).

Institutional Ownership by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.